BG103278A - Medicamentous treatment - Google Patents

Medicamentous treatment

Info

Publication number
BG103278A
BG103278A BG103278A BG10327899A BG103278A BG 103278 A BG103278 A BG 103278A BG 103278 A BG103278 A BG 103278A BG 10327899 A BG10327899 A BG 10327899A BG 103278 A BG103278 A BG 103278A
Authority
BG
Bulgaria
Prior art keywords
medicamentous treatment
coronarovascular
hyperuricaemia
gout
monohydrate
Prior art date
Application number
BG103278A
Other languages
Bulgarian (bg)
English (en)
Inventor
Peter Kelly
Stephan Jones
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG103278A publication Critical patent/BG103278A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
BG103278A 1996-09-25 1999-03-24 Medicamentous treatment BG103278A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619962.5A GB9619962D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005034 WO1998013033A1 (en) 1996-09-25 1997-09-15 Medical treatment

Publications (1)

Publication Number Publication Date
BG103278A true BG103278A (en) 2000-01-31

Family

ID=10800448

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103278A BG103278A (en) 1996-09-25 1999-03-24 Medicamentous treatment

Country Status (26)

Country Link
US (1) US6162831A (xx)
EP (1) EP1007023B1 (xx)
JP (1) JP2001501608A (xx)
KR (1) KR20000048568A (xx)
CN (1) CN1231604A (xx)
AT (1) ATE239460T1 (xx)
AU (1) AU722129B2 (xx)
BG (1) BG103278A (xx)
BR (1) BR9711414A (xx)
CA (1) CA2266438A1 (xx)
DE (1) DE69721838T2 (xx)
DK (1) DK1007023T3 (xx)
ES (1) ES2199374T3 (xx)
GB (1) GB9619962D0 (xx)
HR (1) HRP970519A2 (xx)
HU (1) HUP9904545A3 (xx)
IL (1) IL128851A (xx)
NO (1) NO991425D0 (xx)
NZ (1) NZ334668A (xx)
PL (1) PL332423A1 (xx)
PT (1) PT1007023E (xx)
SK (1) SK32199A3 (xx)
TR (1) TR199900649T2 (xx)
TW (1) TW415842B (xx)
WO (1) WO1998013033A1 (xx)
ZA (1) ZA978573B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
MXPA01009461A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Tratamiento de osteoartritis.
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US9655932B2 (en) * 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
PL375032A1 (en) * 2002-10-05 2005-11-14 Hanmi Pharm.Co, Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
EP1778261A4 (en) * 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
AU2007322477A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
US11179426B2 (en) 2016-12-29 2021-11-23 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
KR20210124958A (ko) * 2018-11-02 2021-10-15 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 국소적으로 적용되는 완충제(buffers)를 사용하는 양이온 과부하 및 전해질 불균형의 위험 가능성 관리를 위한 제형 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
AU4542993A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
JP2001501608A (ja) 2001-02-06
NZ334668A (en) 2000-07-28
IL128851A0 (en) 2000-01-31
HUP9904545A2 (hu) 2000-11-28
SK32199A3 (en) 1999-12-10
GB9619962D0 (en) 1996-11-13
EP1007023A1 (en) 2000-06-14
ES2199374T3 (es) 2004-02-16
DE69721838T2 (de) 2004-01-22
AU4385197A (en) 1998-04-17
NO991425L (no) 1999-03-24
PL332423A1 (en) 1999-09-13
KR20000048568A (ko) 2000-07-25
DE69721838D1 (de) 2003-06-12
AU722129B2 (en) 2000-07-20
EP1007023B1 (en) 2003-05-07
CN1231604A (zh) 1999-10-13
PT1007023E (pt) 2003-08-29
US6162831A (en) 2000-12-19
ZA978573B (en) 1999-03-25
HRP970519A2 (en) 1998-08-31
CA2266438A1 (en) 1998-04-02
IL128851A (en) 2001-08-26
WO1998013033A1 (en) 1998-04-02
TR199900649T2 (xx) 1999-07-21
BR9711414A (pt) 2000-04-25
DK1007023T3 (da) 2003-08-25
ATE239460T1 (de) 2003-05-15
TW415842B (en) 2000-12-21
HUP9904545A3 (en) 2000-12-28
NO991425D0 (no) 1999-03-24

Similar Documents

Publication Publication Date Title
BG103278A (en) Medicamentous treatment
PH31220A (en) Medical treatment.
BG103277A (en) Application of sibutramine analogues for the prevention of diabetes development
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
EP0936217A4 (en) 1-PHENYLPYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATION
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
WO2000056315A8 (en) Treatment of pain
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
MXPA01009467A (es) Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
MXPA03011193A (es) Nuevos compuestos utiles en enfermedad de reflujo.
MY133438A (en) Morpholinobenzamide salts
ZA877454B (en) Therapeutic agent for the treatment of peptic ulcer disease
AU4373785A (en) Dibenzyl-imidazole derivatives
MXPA01009461A (es) Tratamiento de osteoartritis.
MXPA01009463A (es) Tratamiento de hernia hiatial.
AU2001262786A1 (en) Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes